Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK publishes Annual Report 2023

1 Mar 2024 12:15

RNS Number : 2981F
GSK PLC
01 March 2024
 

 

GSK plc

(the 'Company')

 

Publication of Annual Report 2023

 

 

The Company has today published on its website www.annualreport.gsk.com its Annual Report for the year ended 31 December 2023 ('Annual Report 2023').

 

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2023 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

A hard copy version of the Annual Report 2023 and the Notice of Annual General Meeting 2024 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 25 March 2024. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

 

This announcement is not a substitute for reading the Annual Report 2023 in full.

 

Additional Information

 

For the purposes of complying with the FCA's Disclosure and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2023. The Annual Report 2023 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

 

This announcement is made in accordance with DTR 6.3.5R(1A).

 

V A Whyte

Company Secretary

 

1 March 2024

 

?

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEAADFEFALEFA
Date   Source Headline
15th Jan 201912:00 pmRNSGlaxoSmithKline Extends Tender Offer for TESARO
11th Jan 20194:32 pmRNSDirector/PDMR Shareholding
11th Jan 20194:25 pmRNSDirector/PDMR Shareholding
2nd Jan 20191:45 pmRNSTotal Voting Rights
20th Dec 20185:15 pmRNSDirector/PDMR Shareholding
19th Dec 20187:00 amRNSGSK and Pfizer create new Consumer Healthcare JV
14th Dec 20181:20 pmRNSGSK Commences Tender Offer for TESARO Inc.
12th Dec 20184:35 pmRNSDirector/PDMR Shareholding
4th Dec 201810:07 amRNSDirector/PDMR Shareholding
3rd Dec 20182:00 pmRNSTotal Voting Rights
3rd Dec 201812:02 pmRNSGSK reaches agreement to acquire TESARO
3rd Dec 20188:35 amRNSGSK to divest Horlicks to Unilever
30th Nov 20184:40 pmRNSSecond Price Monitoring Extn
30th Nov 20184:35 pmRNSPrice Monitoring Extension
29th Nov 20183:40 pmRNSDirector/PDMR Shareholding
29th Nov 201811:45 amRNSGSK - Update on Review of Horlicks
27th Nov 20183:25 pmRNSBlock listing Interim Review
22nd Nov 20181:02 pmRNSGSK publishes 2019 Dividend Dates
12th Nov 20182:45 pmRNSDirector/PDMR Shareholding
12th Nov 20189:00 amRNSBlocklisting Application
8th Nov 201812:43 pmRNSDirector Declaration
2nd Nov 20184:15 pmRNSDirector/PDMR Shareholding
1st Nov 20181:40 pmRNSTotal Voting Rights
31st Oct 20182:15 pmRNSViiV positive phIII results with fostemsavir
31st Oct 201812:07 pmRNSSecond Price Monitoring Extn
31st Oct 201812:02 pmRNSPrice Monitoring Extension
31st Oct 201812:00 pmRNS3rd Quarter Results
30th Oct 20182:30 pmRNSViiV: positive data for long-acting injectable
29th Oct 201810:00 amRNSViiV - three-year data for long-acting injectable
18th Oct 20184:00 pmRNSViiV submits HIV 2DR regulatory application to FDA
18th Oct 20189:34 amRNSDirector/PDMR Shareholding
17th Oct 20185:56 pmRNSDirector/PDMR Shareholding
17th Oct 20185:50 pmRNSDirector/PDMR Shareholding
17th Oct 201811:30 amRNSDirector/PDMR Shareholding
16th Oct 20184:53 pmRNSDirector/PDMR Shareholding
16th Oct 20189:30 amRNSDirector/PDMR Shareholding
16th Oct 20189:30 amRNSDirector/PDMR Shareholding
10th Oct 20183:30 pmRNSDirector/PDMR Shareholding
1st Oct 20181:58 pmRNSTotal Voting Rights
27th Sep 20184:35 pmRNSDirector/PDMR Shareholding
21st Sep 201812:30 pmRNSCHMP recommends expansion of Trelegy COPD label
14th Sep 20189:00 amRNSViiV submits HIV 2DR regulatory application to EMA
12th Sep 20185:43 pmRNSDirector/PDMR Shareholding
10th Sep 20188:00 amRNSNew analysis on efficacy of anti-IL5 biologics SEA
10th Sep 20187:00 amRNSGSK receives CRL from FDA for mepolizumab in COPD
7th Sep 20182:24 pmRNSDirector/PDMR Shareholding
7th Sep 20182:18 pmRNSDirector/PDMR Shareholding
3rd Sep 20185:00 pmRNSTotal Voting Rights
30th Aug 20185:12 pmRNSGSK publishes Q4 2018 Dividend Dates
30th Aug 20188:12 amRNSEU approve Nucala in severe asthma in children

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.